Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what discussions she has had with relevant stakeholders on tackling shortages of Etoricoxib.

The Department is aware that a supplier of etoricoxib 60 milligram tablets is experiencing a supply issue. We have been working with that supplier to address the issue, and resupply is expected in early May 2024. We have worked with alternative suppliers to ensure they can cover the gap in the market in the meantime.

The medicine supply chain is highly regulated, complex, and global. Supply disruption is an issue which affects the United Kingdom, as well as other countries around the world. There can be a variety of causes, including manufacturing issues, problems with access to raw ingredients, and sudden spikes in demand.

Whilst we can’t always prevent supply issues, the Department has well-established tools and processes to manage them, in order to mitigate risks to patients. We work closely with the pharmaceutical industry, NHS England, the Medicines and Healthcare products Regulatory Agency, and others operating in the supply chain to help ensure patients continue to have access to suitable medicines when supply is disrupted.